Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA plus )

被引：23

作者：

Falantes, Jose ^{[1
]}

Pleyer, Lisa ^{[2
,3
,4
]}

Thepot, Sylvain ^{[5
]}

Almeida, Antonio M. ^{[6
]}

Maurillo, Luca ^{[7
]}

Martinez-Robles, Violeta ^{[8
]}

Stauder, Reinhard ^{[9
]}

Itzykson, Raphael ^{[10
]}

Pinto, Ricardo ^{[11
]}

Venditti, Adriano ^{[7
]}

Bargay, Joan ^{[12
]}

Burgstaller, Sonja ^{[13
]}

Pilar Martinez, Maria ^{[14
]}

Seegers, Valerie ^{[15
]}

Cortesao, Emilia ^{[16
]}

Angeles Foncillas, Maria ^{[17
]}

Gardin, Claude ^{[15
]}

Montesinos, Pau ^{[18
]}

Musto, Pellegrino ^{[19
]}

Fenaux, Pierre ^{[10
]}

Greil, Richard ^{[2
,3
,4
]}

Angel Sanz, Miguel ^{[18
]}

Ramos, Fernando ^{[8
,20
]}

机构：

[1] Univ Hosp Virgen del Rocio, Dept Hematol, Seville, Spain

[2] Paracelsus Med Univ Hosp Salzburg, Med Dept Hematol & Med Oncol Hemostaseol Rheumato, Ctr Oncol, Lab Immunol & Mol Canc Res, Salzburg, Austria

[3] Ctr Clin Canc & Immunol Trials, Salzburg Canc Res Inst, Salzburg, Austria

[4] Canc Cluster Salzburg, Salzburg, Austria

[5] CHU Angers, Dept Blood Dis Hematol, Angers, France

[6] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Lisbon, Portugal

[7] Univ Rome, Dept Hematol, Tor Vergata Fdn Polyclin, Rome, Italy

[8] Univ Hosp, Dept Hematol, Leon, Spain

[9] Innsbruck Med Univ, Dept Internal Med Hematol & Oncol 5, Innsbruck, Austria

[10] Paris VII Univ, St Louis Hosp, APHP, Dept Hematol, Paris, France

[11] Hosp Sao Joao, Dept Hematol, Porto, Portugal

[12] Son Llatzer Hosp, Dept Hematol, Palma De Mallorca, Spain

[13] Wels Grieskirchen Hosp, Dept Internal Med 4, Wels, Austria

[14] Doce Octubre Univ Hosp, Dept Hematol, Madrid, Spain

[15] Paris XIII Univ, Avicenne Hosp, APHP, Dept Hematol, Bobigny, France

[16] Ctr Hosp Univ Coimbra, Dept Hematol, Coimbra, Portugal

[17] Infanta Leonor Univ Hosp, Dept Hematol, Madrid, Spain

[18] La Fe Univ Hosp, Dept Hematol, Valencia, Spain

[19] IRCCS CROB Referral Canc Ctr Basilicata, Sci Direct, Rionero In Vulture, Italy

[20] Univ Leon, Inst Biomed, Leon, Spain

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 05期

关键词：

Acute myeloid leukemia; elderly; azacitidine; MRC; LRF risk score; E-ALMA; RISK MYELODYSPLASTIC SYNDROME; WORLD-HEALTH-ORGANIZATION; COUNCIL AML11 TRIAL; LOW-DOSE CYTARABINE; PHASE-III TRIAL; INTENSIVE CHEMOTHERAPY; SUPPORTIVE CARE; TREATMENT OUTCOMES; EARLY DEATH; SURVIVAL;

D O I：

10.1080/10428194.2017.1365854

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N=710) unfit for IC from different national registries (E-ALMA+series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8-16), 12.4 (95% CI, 9.9-14.8), and 8.1 months (95% CI, 7-9.1), respectively (p=.0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.

引用

页码：1113 / 1120

页数：8

共 35 条

[1] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[2]

[Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[3] Age and acute myeloid leukemia [J].

Appelbaum, FR ;

Gundacker, H ;

Head, DR ;

Slovak, ML ;

Willman, CL ;

Godwin, JE ;

Anderson, JE ;

Petersdorf, SH .

BLOOD, 2006, 107 (09) :3481-3485

[4] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[5] Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia [J].

Arthur, Christopher ;

Cermak, Jaroslav ;

Delaunay, Jacques ;

Mayer, Jiri ;

Mazur, Grzegorz ;

Thomas, Xavier ;

Wierzbowska, Agnieszka ;

Jones, Mark M. ;

Berrak, Erhan ;

Kantarjian, Hagop .

JOURNAL OF BLOOD MEDICINE, 2015, 6 :25-29

[6] Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network [J].

Bories, Pierre ;

Bertoli, Sarah ;

Berard, Emilie ;

Laurent, Julie ;

Duchayne, Eliane ;

Sarry, Audrey ;

Delabesse, Eric ;

Beyne-Rauzy, Odile ;

Huguet, Francoise ;

Recher, Christian .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (12) :E244-E252

[7] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[8] Treatment of acute myeloid leukemia: are we making progress? [J].

Burnett, Alan K. .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2012, :1-6

[9] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[10] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

← 1 2 3 4 →